Nervio Overview
Nervio is a digital health start-up applying data science and artificial intelligence in the field of neurophysiology. The company's mission is to prevent avoidable paralysis and severe neurologic complications during surgeries. Nervio's AI-powered neuromonitoring solution alerts clinicians in real time to any neurological complications right in the operating room, thus minimizing permanent nerve injuries.
Cumulative Funding Raised Over Time ($)
$5.5MSep 2025
Latest News
growth-positive
Nervio appoints Dr. Richard Vogel as US CEO | CTech
Nervio, a company specializing in AI-based neurophysiologist support systems, has appointed Dr. Richard Vogel as its U.S. CEO. The company is expanding its U.S. operations and raising a post-Seed round, supplemented by a grant from the Israel Innovation Authority. Nervios technology aims to support neurophysiologists in managing the increasing demand for spine surgeries, which are expected to rise by 40% over the next decade. The AI system, developed over five years, is designed to reduce workload and improve patient care. Dr. Vogel, a leader in neurophysiological monitoring, sees this as a significant advancement in the field, providing much-needed support to the workforce.
Management ChangesInvestmentExpand
growth-positive
10 Israeli companies selected for Assuta's 'RISE With US' program | CTech
Assuta Medical Centers innovation arm, Rise, has announced the 10 startups selected for the second cohort of its RISE with US program. The program aims to connect startups to the global healthcare market, with a focus on the American market. The startups, chosen from 111 applicants, are developing digital health solutions using artificial intelligence and big data. The program is supported by AWS and Nvidia, as well as venture capital funds from LionBird and eHealth Ventures. The startups will have access to Assuta Medical Centers, receive clinical guidance from physicians, and gain access to a network of contacts in the healthcare industry.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6.75M |
| Last funding | $5.5M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.nervio.ai |
| Careers | Careers page |
Locations
Misgav, Israel
New York, NY, USA
Photos & Videos
No files yet
Nervio Business
Business models
B2B
Product stage
Beta
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Artificial IntelligenceMachine LearningTags (9)
alert-systemartificial-intelligencemachine-learningneurosciencedigital-healthcareoperating-roomsreal-timemonitoringdecision-supportGeographic Markets
North AmericaEuropeNervio Financials
$6.75M
Total funding
Undisclosed
Capital raised
$5.5M
Last funding
Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$5.5MSep 2025
Private Equity Funding
Seed
Sep 2025
$5.5M
Merchavia Holdings, eHealth Ventures
Non-Equity Funding
GrantEvent
Dec 2024
$1.25M
Israel Innovation Authority (Lead)
Nervio Lifecycle
Cumulative Funding Raised Over Time
$5.5MSep 2025
All Events
Seed
Sep 2025
$5.5M
Merchavia Holdings, eHealth Ventures
GrantEvent
Dec 2024
$1.25M
Israel Innovation Authority (Lead)
Nervio News
2 articles
growth-positive
Nervio appoints Dr. Richard Vogel as US CEO | CTech
Nervio, a company specializing in AI-based neurophysiologist support systems, has appointed Dr. Richard Vogel as its U.S. CEO. The company is expanding its U.S. operations and raising a post-Seed round, supplemented by a grant from the Israel Innovation Authority. Nervios technology aims to support neurophysiologists in managing the increasing demand for spine surgeries, which are expected to rise by 40% over the next decade. The AI system, developed over five years, is designed to reduce workload and improve patient care. Dr. Vogel, a leader in neurophysiological monitoring, sees this as a significant advancement in the field, providing much-needed support to the workforce.
Management ChangesInvestmentExpand
growth-positive
10 Israeli companies selected for Assuta's 'RISE With US' program | CTech
Assuta Medical Centers innovation arm, Rise, has announced the 10 startups selected for the second cohort of its RISE with US program. The program aims to connect startups to the global healthcare market, with a focus on the American market. The startups, chosen from 111 applicants, are developing digital health solutions using artificial intelligence and big data. The program is supported by AWS and Nvidia, as well as venture capital funds from LionBird and eHealth Ventures. The startups will have access to Assuta Medical Centers, receive clinical guidance from physicians, and gain access to a network of contacts in the healthcare industry.
PartnersInvestment
Nervio Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 19 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Nervio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516111358 |
| Crunchbase | nervio |
| Phone | +97246638883 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-10-01T00:00:00.000Z |
| Created | 2019-02-07T00:00:00.000Z |
| Claimed | Yes |